enGene Therapeutics

ENGNNasdaq Canada Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$131.352 M

$1.96 +2.62%

Close of 21 Sept 2026

Revenue

—

Not reported

Earnings

-$117.3M

Loss-making

Shares outstanding

66,989,466

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Other share classes

enGene Therapeutics lists more than one class of stock. Company figures above cover all classes combined.

ENGNW

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 160 →

#107Molecular PartnersMOLN$149.7M
#108Caribou BiosciencesCRBU$139.4M
#109enGene TherapeuticsENGN$131.4M
#110Neumora TherapeuticsNMRA$130.0M
#111LENZ TherapeuticsLENZ$128.2M

What if enGene Therapeutics were worth as much as…

Open the what-if tool →

Gold $30.3T

$451,741.55

Per share 230,480× higher

Bitcoin $1.72T

$25,662.46

Per share 13,093× higher

Nvidia $5.48T

$81,769.01

Per share 41,719× higher

Or at a round number

$200.0M $500.0M $1.00B $2.00B

Where these numbers come from

Share counts and financials for enGene Therapeutics are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 22 Sept 2026. Read the methodology.